Alessandro Russo, Medical Oncologist and Assistant Professor at Humanitas Clinical Institute of Catania, shared a post on LinkedIn:
“Out now on the official International Association for the Study of Lung Cancer journal JTO (Journal of Thoracic Oncology) our analysis of >80.000 patients with lung cancer using a tissue CGP assay (Foundation One CDx).
This is the largest dataset published to date, demonstrating sufficient enough biomarker prevalence across many histological subtypes of NSCLC, providing reassurance that all NSCLC cases should be considered for biomarker workup. In particular, ~7% of patients with pure squamous cell carcinoma histology are associated with actionable genomic alterations. This data support universal molecular testing across all NSCLC subtypes to ensure equitable access to available therapeutics.
Thanks to my mentor Christian Rolfo, (The Arthur G. James Comprehensive Cancer Center, Columbus, OH, USA), Mana Javey (Roche diagnostics) and Richard SP Huang (Foundation Medicine) for involving me in this great project and thanks to our stellar co-authors Fernando Lopez-Rios (Hospital Universitario 12 de Octubre, Madrid) and Maria E. Arcila (MSKCC) for their invaluable support and expertise.”
Title: Molecular Profiling across 80,000 Patients with Lung Cancer
Authors: Alessandro Russo, Manana Javey, Richard S. P. Huang, Stephanie J. Yaung, Ben Kaplan, Matthew C. Hiemenz, Maria E. Arcila, Fernando Lopez-Rios, Christian Rolfo
Read the Full Article.
Other Articles Featuring Alessandro Russo on OncoDaily.